Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration

04:20 EST 2 Dec 2016 | Pharmaceutical Business Review

Bicycle Therapeutics and AstraZeneca have agreed a $1bn multi-target collaboration across respiratory, cardiovascular and metabolic diseases.

Original Article: Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration


More From BioPortfolio on "Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration"

Quick Search

Relevant Topics

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...